154 related articles for article (PubMed ID: 29164976)
1. Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
Shen Y; Best OG; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2018 Aug; 59(8):1927-1937. PubMed ID: 29164976
[TBL] [Abstract][Full Text] [Related]
2. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
de Rooij MF; Kuil A; Kater AP; Kersten MJ; Pals ST; Spaargaren M
Blood; 2015 Apr; 125(14):2306-9. PubMed ID: 25838279
[No Abstract] [Full Text] [Related]
4. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
5. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
6. Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
Pleyer C; Wiestner A; Sun C
Leuk Lymphoma; 2018 Dec; 59(12):2792-2800. PubMed ID: 29764250
[TBL] [Abstract][Full Text] [Related]
7. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
Fiorcari S; Brown WS; McIntyre BW; Estrov Z; Maffei R; O'Brien S; Sivina M; Hoellenriegel J; Wierda WG; Keating MJ; Ding W; Kay NE; Lannutti BJ; Marasca R; Burger JA
PLoS One; 2013; 8(12):e83830. PubMed ID: 24376763
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
11. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
Hofland T; de Weerdt I; Ter Burg H; de Boer R; Tannheimer S; Tonino SH; Kater AP; Eldering E
J Immunol; 2019 Oct; 203(8):2100-2109. PubMed ID: 31511358
[TBL] [Abstract][Full Text] [Related]
12. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Han TT; Fan L; Li JY; Xu W
Cancer Biol Ther; 2014 Jan; 15(1):3-9. PubMed ID: 24149438
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
15. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Chung C; Lee R
Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
[TBL] [Abstract][Full Text] [Related]
17. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
Front Immunol; 2021; 12():608625. PubMed ID: 33790890
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
Shi Y; Wang G; Muhowski EM; McCaw L; Wang C; Bjarnason G; Woyach JA; Spaner DE
Leukemia; 2019 Jul; 33(7):1650-1662. PubMed ID: 30696950
[TBL] [Abstract][Full Text] [Related]
19. L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo.
Lafouresse F; Bellard E; Laurent C; Moussion C; Fournié JJ; Ysebaert L; Girard JP
Blood; 2015 Sep; 126(11):1336-45. PubMed ID: 26162407
[TBL] [Abstract][Full Text] [Related]
20. Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
de Weerdt I; Hofland T; Lameris R; Endstra S; Jongejan A; Moerland PD; de Bruin RCG; Remmerswaal EBM; Ten Berge IJM; Liu N; van der Stelt M; Faber LM; Levin MD; Eldering E; Tonino SH; de Gruijl TD; van der Vliet HJ; Kater AP
Blood; 2018 Nov; 132(21):2260-2272. PubMed ID: 30213872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]